ORIC PHARMACEUTICALS, INC. Research and Development in Process
ORIC PHARMACEUTICALS, INC. (ORIC) reported Research and Development in Process of $5.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-16
- ORIC PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-12-31 was $0.00.
- ORIC PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-09-30 was $5.00M.
- ORIC PHARMACEUTICALS, INC. research and development in process for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. research and development in process for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. research and development in process for fiscal 2022 was $5.00M.
- ORIC PHARMACEUTICALS, INC. research and development in process for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ORIC PHARMACEUTICALS, INC. research and development in process for fiscal 2020 was $24.84M.
- ORIC PHARMACEUTICALS, INC. research and development in process for fiscal 2019 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $5.00M derived: sum of 2 quarters · filed 2023-03-16 | $5.00M 10-K · filed 2023-03-16 | |
| 2022-09-30 | $5.00M 10-Q · filed 2022-11-07 | $5.00M 10-Q · filed 2022-11-07 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 10-K · filed 2023-03-16 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | ||
| 2020-12-31 | $11.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $24.84M derived: sum of 2 quarters · filed 2022-03-21 | $24.84M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $12.97M 10-Q · filed 2021-11-08 | $12.97M 10-Q · filed 2021-11-08 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |